Abstract
Chondroitin sulphate captured an increasing amount of attention in the field of drug delivery systems. Nanoparticles and chondroitin sulphate were combined in different ways to form effective target nanocarriers. The study aimed to evaluate the biomedical application of chondroitin sulphate with nanoparticles in drug delivery systems. We searched PubMed, Google Scholar, and MEDLINE for studies that included data for the application of chondroitin sulphate and nanoparticles in targeting drug delivery published in English up to 25 February 2020. OHAT (Office of Health Assessment and Translation) Risk-of-Bias Tool was used to assessing the quality and risk of bias of each study. We performed a qualitative synthesis of findings from included studies. The toxicity of developed drugs has been evaluated using cell viability percentage and 50% inhibitory concentration of drugs. Twenty original articles reported the application of chondroitin sulphate on drug delivery systems were selected. Drug loading and encapsulation efficiency were from 2% to 16.1% and from 39.50% to 93.97%, respectively. The drug release was fast at start time and followed by a slow and sustain released stage. The risk of bias was rated as high in two out of twenty studies. Most of the studies presented baseline characteristics and outcomes appropriately.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
